And I think most people don't want to give themselves that risk
In any of these cases, the safest course is to discard the vial and start fresh
DOI.org (Crossref) , Molecules , vol

however, the safety and efficacy of such therapy have not been systematically evaluated Risk factors of statinfibrate-related myopathy include advanced age, female gender, low BMI, renal disease, diabetes mellitus, hypothyroidism, multisystem disease, fever, surgery, trauma, and strenuous physical exercise The likelihood and/or severity of myopathy also depend on pharmacologic properties of the statin and the fibrate, such as their enzymatic metabolism or excretion and/or their protein-regulated intercellular transport Fenofibrate or fenofibric acid may be fibrates of choice for statinfibrate therapy because, according to pharmacokinetic and postmarketing data, they are associated with lower risks of myopathy (versus gemfibrozil) This is a preview of subscription content, access via your institution Access options Subscribe to this journal Receive 12 print issues and online access $189.00 per year only $15.75 per issue Buy this article Purchase on SpringerLink Instant access to the full article PDF
